WMSA
CERE

Weiss Multi-Strategy Advisers’s Cerevel Therapeutics Holdings, Inc. Common Stock CERE Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio CERE Stock Details CERE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-24,140
Closed -$767K – 760
2023
Q2 		$767K Sell
24,140
-54,563
-69% -$1.67M 0.02% 558
2023
Q1 		$1.92M Buy
+78,703
New +$2.31M 0.05% 430

Other funds holding CERE

BCI
Bain Capital Investors Boston, Massachusetts $3.27B AUM 3.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Weiss Multi-Strategy Advisers's CERE Position: Q3 2023 in Review

Weiss Multi-Strategy Advisers sold out of Cerevel Therapeutics Holdings, Inc. Common Stock (CERE) in Q3 2023, closing a stake of 24,140 shares — an estimated $767K sold.

Weiss Multi-Strategy Advisers first reported a position in CERE in Q1 2023 and held it in 2 quarters. The position peaked at $1.92M in Q1 2023. 119 funds tracked by Wall St. Rank hold CERE as of Q3 2023.

  • Weiss Multi-Strategy Advisers reported no remaining Cerevel Therapeutics Holdings, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 24,140 Cerevel Therapeutics Holdings, Inc. Common Stock shares in Q3 2023, an estimated $767K.
  • Weiss Multi-Strategy Advisers first reported a position in Cerevel Therapeutics Holdings, Inc. Common Stock in Q1 2023 and held it in 2 quarters.
  • Weiss Multi-Strategy Advisers's Cerevel Therapeutics Holdings, Inc. Common Stock position peaked at $1.92M in Q1 2023.
  • 119 funds tracked by Wall St. Rank held Cerevel Therapeutics Holdings, Inc. Common Stock as of Q3 2023.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2023, filed 14 Nov 2023.